MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
May 29, 2024 07:00 ET
|
MediWound Ltd.
NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H...
MediWound to Report First Quarter 2024 Financial Results
May 22, 2024 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024 08:00 ET
|
MediWound Ltd.
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the...
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024 07:00 ET
|
MediWound Ltd.
$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to begin Phase III in the second half of 2024$42...
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will...
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
February 12, 2024 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of...
MediWound to Participate in Two Upcoming Investor Conferences
February 05, 2024 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
January 09, 2024 07:00 ET
|
MediWound Ltd.
If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S. NexoBrid is already approved for use for burn patients across all age...
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
December 28, 2023 07:00 ET
|
MediWound Ltd.
YAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair,...
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
December 21, 2023 08:00 ET
|
MediWound Ltd.
YAVNE, Israel, Dec. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the publication of a...